Are Short Sellers On to Something at Navidea Biopharmaceuticals?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Since everyone loves a winner, it's reasonable to assume that everyone hates a loser -- everyone but short sellers, at least. These contrarian investors bet that hot stocks are primed to fall, aiming to turn their pessimism into profits.

Below, we take a look at biotech Navidea Biopharmaceuticals (NYSEMKT: NAVB  ) , whose shares sold short, according to The Wall Street Journal, jumped 6%. That amounts to more than 17% of its float so its short interest ratio is 18 days to cover, or the number of days it would take to completely buy back all the shares sold short. The Motley Fool thinks seven days is a lot so it's always possible we could see a short squeeze, but let's see if the specialty pharma still has the power to make short work of short sellers.

Navidea Biopharmaceuticals snapshot



Market Cap

$361 million

Revenues (TTM)

>$1 million

1-Year Stock Return


Estimated 5-Year EPS Growth


Return on Investment


Dividend and Yield


Recent Price


Shares Short Feb. 15

19.3 million

Shares Short Jan. 31

18.2 million 

% Change


CAPS Rating


Sources:, N/A = not available; Navidea does not pay a dividend.

Just because the shorts are piling in doesn't mean you should, too. Such stocks could have serious problems that warrant their short interest, but they might also just be stricken by short-term troubles. Only Foolish due diligence will tell you for certain.

The short story
Navidea's lead product is Lymphoseek, a marker used to determine the spread of certain solid-tumor cancers into the lymphatic system, which has the potential to be a top-tier targeted imaging agent for lymphatic mapping. Following the disappointment associated with receiving a complete response letter from the FDA last September, Navidea finally has a PDUFA date at the end of next month that should determine once and for all whether it has addressed the regulatory agency's concerns.

Fortunately, those issues centered on its contract manufacturing partners and not the imaging agent's efficacy or safety, so considering it also filed a marketing authorization application with the European EMA, there might be some sense behind investors feeling confident that it has.

If the FDA does give Lymphoseek its imprimatur, Navidea and its U.S. marketing partner, Cardinal Health (NYSE: CAH  ) , plan to hit the ground running. There's a worldwide market opportunity approaching $450 million, depending on who's doing the counting, with the U.S. representing almost half of it at $200 million. The EU is second with $70 million, according to Navidea, and the rest of the world comes in at $180 million.

Of course, Navidea won't recognize all that revenue because that's just the addressable market. It's going to have to split the proceeds with Cardinal, which also has the responsibility for determining what price to sell the agent (analysts have pegged it at around $400 per treatment ). As they're also entitled to half the U.S. sales, it's going to be a much smaller number that ends up on Navidea's top line. Short sellers may agree there's an opportunity here, but it's likely a far smaller one than longs are suggesting.

Burning down the house
Making sure there's enough cash to cross the finish line is another concern, and my Foolish colleague Rich Smith recently noted Navidea has been burning through cash like a house afire. It's had to tap the public equity markets on several occasions recently to give itself a cushion, but at the end of January it issued yet another 1.5 million shares in an effort to raise $4.4 million more.

Investors might be more worried about the dilution their suffering if all Navidea had was just that one marker in its portfolio. But because it is also actively developing three additional radiopharmaceutical agent platforms -- NAV4694 for diagnosing Alzheimer's, NAV5001 for diagnosing Parkinson's, and RIGScan to help surgeons, particularly, to locate colorectal cancer -- they're likely more willing to cut it some slack for the time being. Success with Lymphoseek will give it the wherewithal to finance its other programs, though don't be surprised if after approval and its stock prices spikes Navidea quickly hits the equity market again for more fast cash.

While NAV4694 is probably the next best thing it has with plans for commencing phase 3 studies early this year, it still means we won't see revenues from it until 2016 at the earliest. Worse yet, Eli Lilly (NYSE: LLY  ) already won FDA approval last year for an Alzheimer's disease imaging agent  and it received the European nod in January.

With NAV5001 and RigScan even further out on the schedule -- RigScan is essentially a backburner project at this point -- Navidea needs Lymphoseek more than ever and the short sellers are betting it will fall short.

Don't sell yourself short
No doubt this moment has been a long time coming and harboring some skepticism isn't exactly unwarranted, but I'm willing to bet it does make it over the top, so I'm rating Navidea on Motley Fool CAPS to outperform the broad market indexes. 

Share your views in the comments box below on whether short sellers should be squeezed till it hurts or if the stock ought to be shorted till the sun don't shine.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more, click here to claim your copy today.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2297338, ~/Articles/ArticleHandler.aspx, 9/25/2016 1:57:02 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:02 PM
CAH $77.66 Up +0.10 +0.13%
Cardinal Health CAPS Rating: ****
LLY $81.16 Down -0.13 -0.16%
Eli Lilly and Co. CAPS Rating: ***
NAVB $0.93 Down -0.06 -5.85%
Navidea Biopharmac… CAPS Rating: *